Insulin Drug Pricing Report & Consumer Protection

Current understanding

Michigan’s Consumer Protection Act (1976 PA 331) is being considered as a vehicle for insulin drug pricing transparency. HB6132 would add sec. 9b requiring the Department of Attorney General to produce a report on insulin drug pricing, situating insulin affordability within the state’s unfair trade practices framework rather than through insurance-mandate mechanisms.

Evidence log

• 2026-05-12 — Health: pharmaceuticals; reports on certain costs and other information associated with prescription drugs; require manufacturers of prescription drugs to file with the department. Creates new act.: cross-connection with prescription-drug-manufacturer-cost-reporting: Insulin pricing reports are a narrower analog to the broader manufacturer cost-reporting duty proposed here. (novelty: 3)
• 2026-07-31 — Attorney General v Eli Lilly and Company: cross-connection with prescription-drug-pricing-mcpa: The Eli Lilly ruling clears the path for the Attorney General’s MCPA investigation into insulin list-price practices, directly tied to insulin drug pricing consumer protection efforts. (novelty: 4)
• 2026-06-10 — Insurance: health insurers; cost-sharing for insulin coverage; eliminate. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406qq.: cross-connection with insulin-copay-cap: Insurance-side elimination of insulin cost-sharing (SB1033) complements the Attorney General insulin pricing report requirement (HB6132) as parallel affordability interventions. (novelty: 2)
• 2026-06-17 — Insurance: health insurers; limit amount on co-pay for prescription insulin; provide for. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406qq.: cross-connection with insulin-copay-cap: Two complementary Michigan insulin-affordability tracks: HB6101 caps insurer co-pays (insurance code), while the parallel AG insulin drug pricing report bill uses consumer protection law to surface pricing information. (novelty: 2)
• 2026-06-25 — Consumer protection: unfair trade practices; insulin drug pricing report; require by the department of attorney general. Amends 1976 PA 331 (MCL 445.901 - 445.922) by adding sec. 9b.: cross-connection with prescription-drug-copay-accumulator: Both address prescription drug affordability but through distinct vehicles — insurance-code copay rules vs. Consumer Protection Act pricing transparency. (novelty: 2)

Open questions

Related